R&D

Innovation to Beauty and Health

Pipeline

Pipeline

Hugel continues to research the next generation of biopharmaceuticals.

  • STEP 1

    Candidate selection

    Screening and securing candidates fit for disease areas and therapeutic purposes

  • STEP 2

    Nonclinical study

    Obtaining the property or safety data of the test substance using animals

  • STEP 3

    Clinical study

    Confirmation of safety and effectiveness for humans

  • STEP 4

    Approval

    Safety, efficacy, standards and test methods, approval through drug manufacturing and quality control assessment

Pipeline Indication Candidate selection Nonclinical study Clinical phase I Clinical phase II Clinical phase III Approval
Botulax® Blepharospasm
Glabellar lines
Post-stroke upperlimb spasticity
Foot deformity in pediatric cerebral palsy
Crow’s feet
Overactive bladder
Cervical dystonia
Benign masseteric hypertrophy
Botulinum toxin formulation development Pain-reducing liquid formulation Glabellar lines,hyperhidrosis
Micro-needle toxin formulation Hyperhidrosis
RNAi
(New medicine)
Intractable hypertrophic scar
The Chaeum Temporary improvement of facial wrinkles
Penile enhancement
Increase volumizing of facial part
Pharmaceutical-HG301 Submental fat reduction
Pipeline Indication Candidate selection Nonclinical study Clinical phase I Clinical phase II Clinical phase III Approval
Botulax® Blepharospasm
Glabellar lines
Post-stroke upperlimb spasticity
Foot deformity in pediatric cerebral palsy
Crow’s feet
Overactive bladder
Cervical dystonia
Benign masseteric hypertrophy
Botulinum toxin formulation development Pain-reducing liquid formulation Glabellar lines,hyperhidrosis
Micro-needle toxin formulation Hyperhidrosis
RNAi
(New medicine)
Intractable hypertrophic scar
The Chaeum Temporary improvement of facial wrinkles
Penile enhancement
Increase volumizing of facial part
Pharmaceutical-HG301 Submental fat reduction